These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 24329887)

  • 1. Genetic correction using engineered nucleases for gene therapy applications.
    Li HL; Nakano T; Hotta A
    Dev Growth Differ; 2014 Jan; 56(1):63-77. PubMed ID: 24329887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene targeting technologies in rats: zinc finger nucleases, transcription activator-like effector nucleases, and clustered regularly interspaced short palindromic repeats.
    Mashimo T
    Dev Growth Differ; 2014 Jan; 56(1):46-52. PubMed ID: 24372523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress in genome engineering techniques in the silkworm, Bombyx mori.
    Daimon T; Kiuchi T; Takasu Y
    Dev Growth Differ; 2014 Jan; 56(1):14-25. PubMed ID: 24175911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plant genome engineering in full bloom.
    Lozano-Juste J; Cutler SR
    Trends Plant Sci; 2014 May; 19(5):284-7. PubMed ID: 24674878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN.
    Ul Ain Q; Chung JY; Kim YH
    J Control Release; 2015 May; 205():120-7. PubMed ID: 25553825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome Editing and Its Applications in Model Organisms.
    Ma D; Liu F
    Genomics Proteomics Bioinformatics; 2015 Dec; 13(6):336-44. PubMed ID: 26762955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9.
    LaFountaine JS; Fathe K; Smyth HD
    Int J Pharm; 2015 Oct; 494(1):180-94. PubMed ID: 26278489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclease-mediated genome editing: At the front-line of functional genomics technology.
    Sakuma T; Woltjen K
    Dev Growth Differ; 2014 Jan; 56(1):2-13. PubMed ID: 24387662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted mutagenesis in Zea mays using TALENs and the CRISPR/Cas system.
    Liang Z; Zhang K; Chen K; Gao C
    J Genet Genomics; 2014 Feb; 41(2):63-8. PubMed ID: 24576457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of CRISPR/Cas9 genome editing to the study and treatment of disease.
    Pellagatti A; Dolatshad H; Valletta S; Boultwood J
    Arch Toxicol; 2015 Jul; 89(7):1023-34. PubMed ID: 25827103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery technologies for genome editing.
    Yin H; Kauffman KJ; Anderson DG
    Nat Rev Drug Discov; 2017 Jun; 16(6):387-399. PubMed ID: 28337020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simple knockout by electroporation of engineered endonucleases into intact rat embryos.
    Kaneko T; Sakuma T; Yamamoto T; Mashimo T
    Sci Rep; 2014 Oct; 4():6382. PubMed ID: 25269785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome editing: the road of CRISPR/Cas9 from bench to clinic.
    Eid A; Mahfouz MM
    Exp Mol Med; 2016 Oct; 48(10):e265. PubMed ID: 27741224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CRISPR-Cas system for plant genome editing: advances and opportunities.
    Kumar V; Jain M
    J Exp Bot; 2015 Jan; 66(1):47-57. PubMed ID: 25371501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CRISPR/Cas9 system for plant genome editing and beyond.
    Bortesi L; Fischer R
    Biotechnol Adv; 2015; 33(1):41-52. PubMed ID: 25536441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted genome editing tools for disease modeling and gene therapy.
    Cai M; Yang Y
    Curr Gene Ther; 2014 Feb; 14(1):2-9. PubMed ID: 24665839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding and Editing the Zebrafish Genome.
    Varshney GK; Sood R; Burgess SM
    Adv Genet; 2015; 92():1-52. PubMed ID: 26639914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9 and TALEN-mediated knock-in approaches in zebrafish.
    Auer TO; Del Bene F
    Methods; 2014 Sep; 69(2):142-50. PubMed ID: 24704174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic editing opens new avenues for zebrafish as a model for neurodegeneration.
    Schmid B; Haass C
    J Neurochem; 2013 Nov; 127(4):461-70. PubMed ID: 24117801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.